thiotepa has been researched along with Sarcoma, Ewing in 14 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Sarcoma, Ewing: A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a patient with renal insufficiency (creatinine clearance, CL(cr) = 38 mL/min) who received high-dose chemotherapy with cyclophosphamide (1,500 mg/m(2) day(-1)), thiotepa (120 mg/m(2) day(-1)) and carboplatin (AUC = 5 mg min/mL day(-1)) for four consecutive days." | 7.75 | Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency. ( Beijnen, JH; Ekhart, C; Huitema, AD; Kerst, JM; Rodenhuis, S, 2009) |
| "We report a patient with renal insufficiency (creatinine clearance, CL(cr) = 38 mL/min) who received high-dose chemotherapy with cyclophosphamide (1,500 mg/m(2) day(-1)), thiotepa (120 mg/m(2) day(-1)) and carboplatin (AUC = 5 mg min/mL day(-1)) for four consecutive days." | 3.75 | Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency. ( Beijnen, JH; Ekhart, C; Huitema, AD; Kerst, JM; Rodenhuis, S, 2009) |
| " Whenever one patient at one dosage level showed a grade III or grade IV reversible toxicity, additional patients were admitted (one by one) up to a maximum number of 6." | 2.69 | Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors. ( Bella, S; Burnelli, R; Garaventa, A; Locatelli, F; Melchionda, F; Paolucci, G; Pession, A; Prete, A, 1999) |
| "ThioTEPA was administered intravenously every three weeks, at a dose of 65 mg/m2." | 2.68 | A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study. ( Balis, FM; Bleyer, WA; Broxson, E; Geyer, JR; Heideman, R; Krailo, MD; Poplack, D; Sato, JK, 1996) |
| "Melphalan was given i." | 2.68 | High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors. ( Ater, J; Chan, KW; Choroszy, M; Herzog, C; Jaffe, N; Korbling, M; Petropoulos, D, 1997) |
| "Primary Ewing's sarcoma of the spine is reviewed, and seven cases are presented." | 2.38 | Treatment options in primary Ewing's sarcoma of the spine: report of seven cases and review of the literature. ( el-Khoury, GY; Haddad, FS; Haddad, SF; Hitchon, PW; Sharafuddin, MJ, 1992) |
| " The conditioning regimen was well tolerated, without any toxic deaths." | 1.36 | Toxicity of high-dose chemotherapy with etoposide, thiotepa and CY in treating poor-prognosis Ewing's sarcoma family tumors: the experience of the Bambino Gesù Children's Hospital. ( Cozza, R; De Ioris, MA; De Lurentis, C; De Sio, L; Fidani, P; Ilari, I; Jenkner, A; Milano, GM; Pessolano, R, 2010) |
| "All compounds reduced the growth of Ewing tumor cell lines in a dose-dependent manner." | 1.33 | In-vitro toxicity of Ukrain against human Ewing tumor cell lines. ( Boos, J; Köster, J; Lanvers-Kaminsky, C; Nolting, DM; Sandkötter, J; Schröder, A, 2006) |
| "The principles of dose-response and combination chemotherapy were basic to the design of the initial curative standard-dose treatment regimens for leukemias, lymphomas, and testis cancer." | 1.28 | A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. ( Burke, J; Eder, JP; Elias, A; Frei, E; Hunt, M; Schnipper, LE; Schryber, SM; Shea, TC; Siegel, R; Teicher, BA, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 6 (42.86) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Loschi, S | 1 |
| Dufour, C | 1 |
| Oberlin, O | 1 |
| Goma, G | 1 |
| Valteau-Couanet, D | 1 |
| Gaspar, N | 1 |
| Jahnukainen, K | 1 |
| Kallio, P | 1 |
| Koivusalo, A | 1 |
| Saarinen-Pihkala, UM | 1 |
| Ilari, I | 1 |
| De Ioris, MA | 1 |
| Milano, GM | 1 |
| Pessolano, R | 1 |
| De Lurentis, C | 1 |
| De Sio, L | 1 |
| Fidani, P | 1 |
| Jenkner, A | 1 |
| Cozza, R | 1 |
| Lanvers-Kaminsky, C | 1 |
| Nolting, DM | 1 |
| Köster, J | 1 |
| Schröder, A | 1 |
| Sandkötter, J | 1 |
| Boos, J | 1 |
| Ekhart, C | 1 |
| Kerst, JM | 1 |
| Rodenhuis, S | 1 |
| Beijnen, JH | 1 |
| Huitema, AD | 1 |
| Geyer, JR | 1 |
| Balis, FM | 1 |
| Krailo, MD | 1 |
| Heideman, R | 1 |
| Broxson, E | 1 |
| Sato, JK | 1 |
| Poplack, D | 1 |
| Bleyer, WA | 1 |
| Chan, KW | 1 |
| Petropoulos, D | 1 |
| Choroszy, M | 1 |
| Herzog, C | 1 |
| Jaffe, N | 1 |
| Ater, J | 1 |
| Korbling, M | 1 |
| Yonemoto, T | 1 |
| Tatezaki, S | 1 |
| Ishii, T | 1 |
| Satoh, T | 1 |
| Pession, A | 1 |
| Prete, A | 1 |
| Locatelli, F | 1 |
| Bella, S | 1 |
| Melchionda, F | 1 |
| Garaventa, A | 1 |
| Burnelli, R | 1 |
| Paolucci, G | 1 |
| Hawkins, D | 1 |
| Barnett, T | 1 |
| Bensinger, W | 1 |
| Gooley, T | 1 |
| Sanders, J | 1 |
| Kushner, BH | 1 |
| Meyers, PA | 1 |
| Sharafuddin, MJ | 1 |
| Haddad, FS | 1 |
| Hitchon, PW | 1 |
| Haddad, SF | 1 |
| el-Khoury, GY | 1 |
| Eder, JP | 1 |
| Elias, A | 1 |
| Shea, TC | 1 |
| Schryber, SM | 1 |
| Teicher, BA | 1 |
| Hunt, M | 1 |
| Burke, J | 1 |
| Siegel, R | 1 |
| Schnipper, LE | 1 |
| Frei, E | 1 |
| Clément, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Trial of Busulfan, Thiotepa and Melphalan Followed by Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation and Followed by Total Marrow (Skeletal) Irradiation (TMI) in Patients With High-Risk Ewing's Sarcoma, PNET or Rhabdomyosarco[NCT00003081] | Phase 1 | 16 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients[NCT03542097] | 82 participants (Actual) | Observational | 2014-04-15 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thiotepa and Sarcoma, Ewing
| Article | Year |
|---|---|
How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neopl | 2001 |
Treatment options in primary Ewing's sarcoma of the spine: report of seven cases and review of the literature.
Topics: Adolescent; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cervical V | 1992 |
5 trials available for thiotepa and Sarcoma, Ewing
| Article | Year |
|---|---|
Tandem high-dose chemotherapy strategy as first-line treatment of primary disseminated multifocal Ewing sarcomas in children, adolescents and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child; Child, | 2015 |
A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Humans; Neoplasms; Neuroectode | 1996 |
High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 1997 |
Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 1999 |
Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2000 |
7 other studies available for thiotepa and Sarcoma, Ewing
| Article | Year |
|---|---|
High-dose Thiotepa as Consolidation Therapy With Autologous Hematopoietic Stem Cell Transplantation for High-risk Ewing Family Tumors: Single-institution Experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone | 2015 |
Toxicity of high-dose chemotherapy with etoposide, thiotepa and CY in treating poor-prognosis Ewing's sarcoma family tumors: the experience of the Bambino Gesù Children's Hospital.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Chil | 2010 |
In-vitro toxicity of Ukrain against human Ewing tumor cell lines.
Topics: Berberine Alkaloids; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chelidonium; Dose-Response | 2006 |
Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Drug Interacti | 2009 |
[High-dose chemotherapy with autologous peripheral blood stem cell transplantation (PBSCT) for refractory bone and soft tissue sarcomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; | 1999 |
A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1990 |
[The chemotherapy of cancer].
Topics: Adult; Alkylating Agents; Antimetabolites; Antineoplastic Agents; Dactinomycin; Female; Fluorouracil | 1967 |